Gary Fishbein, MD, MPH

Executive Medical Director, Therapeutic Area Medical Lead, Medical Affairs

Gary Fishbein, MD, MPH, Executive Medical Director and Therapeutic Area Lead, Oncology has more than two decades of experience in oncology drug development within biotech, pharma, and CRO. He is a board-certified oncologist with experience across all phase of development in various tumor types such as breast cancer, Hodgkin and non-Hodgkin lymphomas, cutaneous T-cell lymphoma, head and neck cancer, non-small cell lung cancer, prostate cancer, adult leukemia, gastrointestinal cancers, renal cell cancer, gynecologic malignancies, giant cell tumor of tendon sheath, multiple myeloma, and glioblastoma multiforme, to name a few.

He engages with staff to ensure successful integration of feasibility assessments, trial designs, clinical operations, and regulatory processes. A member of the American Society of Clinical Oncology, he has lectured, authored, and co-authored on such indications as T-cell lymphoma, adolescent melanoma, pancreatic cancer, metastatic breast cancer, systemic amyloidosis, acute myeloid leukemia, Hodgkin lymphoma, and hepatocellular carcinoma.

ABOUT GARY FISHBEIN, MD, MPH

Dr. Fishbein’s expertise encompasses oncology treatment and research, clinical plan development, clinical trial design, and delivery of professional training and education. His achievements in oncology include work with solid tumors, breast cancer, Hodgkin and non-Hodgkin lymphomas, cutaneous T-cell lymphoma, head and neck cancer, non-small cell lung cancer, prostate cancer, adult leukemia, gastrointestinal cancers, renal cell cancer, gynecologic malignancies, giant cell tumor of tendon sheath, multiple myeloma, and glioblastoma multiforme. With experience in research organizations, sponsor companies, and academia, he has provided medical and scientific oversight on all aspects of studies, from feasibility to post-study reports. In addition to working on Phase I-IV studies, he has contributed to studies supporting expanded indications for products already released to market. In his current role as Executive Medical Director and Therapeutic Area Medical Lead for Medical Affairs at Worldwide, his medical and scientific expertise inform insights on both clinical operations and study protocols. He engages with staff to ensure successful integration of feasibility assessments, trial designs, clinical operations, and regulatory processes. Extending beyond the research, he engages with Worldwide’s business and marketing groups to communicate our scientific and medical operations within the commercial context. A member of the American Society of Clinical Oncology, he has lectured, authored, and co-authored on such indications as T-cell lymphoma, adolescent melanoma, pancreatic cancer, metastatic breast cancer, systemic amyloidosis, acute myeloid leukemia, Hodgkin lymphoma, and hepatocellular carcinoma.

Dr. Fishbein received his MD from Sidney Kimmel Medical College at Thomas Jefferson University and has certifications in Medical Oncology and Internal Medicine from the American Board of Internal Medicine. He also holds a Master’s in Public Health (MPH) with a concentration in health policy from Drexel University School of Public Health.

ASK DR. FISHBEIN A QUESTION

Submit an RFP. Ask a Question

EXPLORE OTHER WORLDWIDE TEAM

Mireille Cantarini, BSc, MB, ChB, MRCP, FFPM

Senior Medical Director, Medical Affairs, Oncology

Read my bio

Aman Khera

Global Head of Regulatory Strategy

Read my bio

Emile Youssef, MD, PhD

Vice President, Oncology Scientific Solutions

Read my bio